GXJ
BMRN icon

Global X Japan’s BioMarin Pharmaceuticals BMRN Stock Holding History

Global X Japan’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20K Buy
350
+2
+0.6% +$110 ﹤0.01% 303
2026
Q1 		$19.7K Buy
348
+160
+85% +$9.33K ﹤0.01% 266
2025
Q4 		$11.2K Buy
+188
New +$10.2K ﹤0.01% 280

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Global X Japan's BMRN Position: Q2 2026 in Review

Global X Japan increased its BioMarin Pharmaceuticals (BMRN) stake by 0.57% in Q2 2026, buying an estimated $110 and bringing the position to 350 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #303.

Global X Japan first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Global X Japan held 350 shares of BioMarin Pharmaceuticals worth $20K as of Q2 2026.
  • Global X Japan bought 2 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $110.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Global X Japan's portfolio in Q2 2026, its #303 holding.
  • Global X Japan first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Global X Japan's 13F filing for Q2 2026, filed 14 Jul 2026.